-+ 0.00%
-+ 0.00%
-+ 0.00%
Merck Partners With Isomorphic Labs on AI-Driven Cancer Drug Discovery
Share
Listen to the news
Merck Partners With Isomorphic Labs on AI-Driven Cancer Drug Discovery
  • Merck entered a research collaboration with Isomorphic Labs to discover small-molecule drug candidates against a strategically important oncology target.
  • Isomorphic Labs will use its AI drug design engine with proprietary data supplied by Merck to generate molecular designs.
  • The drugmaker will handle preclinical and clinical development, manufacturing and commercialization of products resulting from the collaboration.
  • Isomorphic Labs will receive an upfront payment, with eligibility for milestone payments and tiered royalties on net sales.
  • The agreement also gives Isomorphic Labs an option to co-fund development in exchange for higher royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261119112890) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending